Kymera Therapeutics Inc (NASDAQ:KYMR) shares, rose in value on Friday, March 28, with the stock price down by -1.92% to the previous day’s close as strong demand from buyers drove the stock to $29.62.
Actively observing the price movement in the last trading, the stock closed the session at $30.20, falling within a range of $29.34 and $30.415. The value of beta (5-year monthly) was 2.227. Referring to stock’s 52-week performance, its high was $53.27, and the low was $29.07. On the whole, KYMR has fluctuated by -2.08% over the past month.
With the market capitalization of Kymera Therapeutics Inc currently standing at about $1.92 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 11.38M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that KYMR’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of KYMR currently trading nearly -9.01% and -17.58% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 33.95, while the 7-day volatility ratio is showing 5.76% which for the 30-day chart, stands at 5.85%. Furthermore, Kymera Therapeutics Inc (KYMR)’s beta value is 2.20, and its average true range (ATR) is 1.92.
A comparison of Kymera Therapeutics Inc (KYMR) with its peers suggests the former has fared considerably weaker in the market. KYMR showed an intraday change of -1.92% in last session, and over the past year, it shrunk by -24.99%%.
Data on historical trading for Kymera Therapeutics Inc (NASDAQ:KYMR) indicates that the trading volumes over the past 10 days have averaged 0.49 and over the past 3 months, they’ve averaged 578.15K. According to company’s latest data on outstanding shares, there are 64.89 million shares outstanding.
Nearly 16.91% of Kymera Therapeutics Inc’s shares belong to company insiders and institutional investors own 95.06% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 7.84 million shares as on 2025-03-14, resulting in a short ratio of 10.62. According to the data, the short interest in Kymera Therapeutics Inc (KYMR) stood at 1348.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 7.34 million. The stock has fallen by -26.37% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the KYMR stock heading into the next quarter.
